Ann: First Key Appointments to Medical Advisory Board, page-77

That’s really good feedback on one of the medical advisors and you make a good point about lending their name to something credible. These medical advisors have a reputation to uphold and it’s a commodity that they would protect at all costs. IMO it is great validation of Dr Agarwal and IHL.

Also in my opinion, the IP generated from these four clinical trials is a potential billion dollar opportunity for IHL. It sounds ludicrous to say this at a $50 million market cap, however BOT is now $260 million after their phase 1b trials.

BTW, I think you are spot on that a future M&A between IHL and Cannvalate would be the most likely option. In any case, this is going to be multiples of the current share price in success.